Novel TB Drug Candidates Via The Inhibition Of Lipid I Biosynthesis
Funder
National Health and Medical Research Council
Funding Amount
$780,743.00
Summary
Tuberculosis (TB) is an enormous global health problem with a continuing impact in Australia. TB is now the leading killer of any infectious disease (1.8 million people per year) and the rapid emergence of drug resistant TB infections threatens to prevent efforts to control the disease. This project seeks to develop novel TB drug candidates that operate by preventing the construction of the cell wall by the bacterial agent that causes the disease.
Discovery Of New Tuberculosis Drug Leads Targeting Cell Wall Biosynthesis
Funder
National Health and Medical Research Council
Funding Amount
$714,816.00
Summary
There is a desperate need for the development of new therapies for the treatment of TB due to widespread resistance of Mycobacterium tuberculosis, the causative agent of TB, to current therapies. The overall goal of this research project is to identify new TB drug leads through the development of structural analogues of bacterially-derived natural products called the sansanmycins that inhibit cell wall synthesis in Mycobacterium tuberculosis.
Is Mycobacterium Ulcerans A Zoonotic Agent Spread By Mosquitoes?
Funder
National Health and Medical Research Council
Funding Amount
$335,853.00
Summary
Last year record numbers of a mysterious flesh-eating bacterial disease called Buruli ulcer were reported in Australia. Wild animals such as possums and rats harbour the bacteria in their guts but we don't know how the disease is transmitted to humans. In this project we will work out how the bacteria survives in the guts of animals and how people contract Buruli ulcer. With this information we can stop the spread of this debilitating disease.